Differentiating Crohn's disease(CD) and intestinal tuberculosis(ITB) has remained a dilemma for most of the clinicians in the developing world, which are endemic for ITB, and where the disease burden of inflammato...Differentiating Crohn's disease(CD) and intestinal tuberculosis(ITB) has remained a dilemma for most of the clinicians in the developing world, which are endemic for ITB, and where the disease burden of inflammatory bowel disease is on the rise. Although, there are certain clinical(diarrhea/hematochezia/perianal disease common in CD; fever/night sweats common in ITB), endoscopic(longitudinal/aphthous ulcers common in CD; transverse ulcers/patulous ileocaecal valve common in ITB), histologic(caseating/confluent/large granuloma common in ITB; microgranuloma common in CD), microbiologic(positive stain/culture for acid fast-bacillus in ITB), radiologic(long segment involvement/comb sign/skip lesions common in CD; necrotic lymph node/contiguous ileocaecal involvement common in ITB), and serologic differences between CD and ITB, the only exclusive features are caseation necrosis on biopsy, positive smear for acid-fast bacillus(AFB) and/or AFB culture, and necrotic lymph node on cross-sectional imaging in ITB. However,these exclusive features are limited by poor sensitivity, and this has led to the development of multiple multi-parametric predictive models. These models are also limited by complex formulae, small sample size and lack of validation across other populations. Several new parameters have come up including the latest Bayesian meta-analysis, enumeration of peripheral blood T-regulatory cells, and updated computed tomography based predictive score. However, therapeutic anti-tubercular therapy(ATT) trial, and subsequent clinical and endoscopic response to ATT is still required in a significant proportion of patients to establish the diagnosis. Therapeutic ATT trial is associated with a delay in the diagnosis of CD, and there is a need for better modalities for improved differentiation and reduction in the need for ATT trial.展开更多
Background： Tuberculosis （TB） remains a worldwide problem. Intestinal TB （ITB） constitutes a major public health problem in developing countries and has been associated with significant morbidity and mortality. T...Background： Tuberculosis （TB） remains a worldwide problem. Intestinal TB （ITB） constitutes a major public health problem in developing countries and has been associated with significant morbidity and mortality. The aim of this study was to characterize the clinical, radiological, endoscopic, and pathological features of ITB and to define the strategy for establishing the diagnosis. Methods： A retrospective study （from January 2000 to June 2015） was carried out in Peking Union Medical College Hospital and all hospitalized cases were diagnosed as ITB during the study period were included. The relevant clinical information, laboratory results, microbiological, and radiological investigations were recorded. Results： Of the 85 cases, 61 cases （71.8%） were ranged from 20 to 50 years. The ileocecal region was involved in about 83.5% （71/85） of patients. About 41.2% （35/85） of patients had co-existing extra ITB, especially active pulmonary TB. Abdominal pain （82.4%） was the most common presenting symptom followed by weight loss （72.9%） and fever （64.7%）. Both T-cell spot of TB test （T-SPOT.TB） and purified protein derivatives （PPD） tests were performed in 26 patients： 20 （76.9%） positive T-SPOT.TB and 13 （50.0%） positive PPD were detected, with a statistical significant difference （P- 0.046）. Twenty cases （23.5%） were histopathology and/or pathogen confirmed TB; 27 cases （31.8%） were diagnosed by clinical manifestation consistent with ITB and evidence of active extra ITB; 38 cases （44.7%） were diagnosed by good response to diagnostic anti-TB therapy. Conclusions： ITB is difficult to diagnose even with modem medical techniques due to its nonspecific clinical and laboratory features. At present, combination of clinical, endoscopic, radiological, and pathological features continues to be the key to the diagnosis of ITB.展开更多
AIM:To investigate the clinical usefulness of interferon-gamma release assays(IGRAs)in the differential diagnosis of intestinal tuberculosis(ITB)from Crohn’s disease(CD)by meta-analysis.METHODS:A systematic search of...AIM:To investigate the clinical usefulness of interferon-gamma release assays(IGRAs)in the differential diagnosis of intestinal tuberculosis(ITB)from Crohn’s disease(CD)by meta-analysis.METHODS:A systematic search of English language studies was performed.We searched the following databases:Medline,Embase,Web of Science and the Cochrane Library.The Standards for Reporting Diagnostic Accuracy initiative and Quality Assessment for Studies of Diagnostic Accuracy tool were used to assess the methodological quality of the studies.Sensitivity,specificity,and other measures of the accuracy of IGRAs in the differential diagnosis of ITB from CD were pooled and analyzed using random-effects models.Receiver operating characteristic curves were applied to summarize overall test performance.Two reviewers independently judged study eligibility while screening the citations.RESULTS:Five studies met the inclusion criteria.The average inter-rater agreement between the two reviewers for items in the quality checklist was 0.95.Analysis of IGRAs for the differential diagnosis of ITB from CD produced summary estimates as follows:sensitivity,0.74(95%CI:0.68-0.80);specificity,0.87(95%CI:0.82-0.90);positive likelihood ratio,5.98(95%CI:3.79-9.43);negative likelihood ratio,0.28(95%CI:0.18-0.43);and diagnostic odds ratio,26.21(95%CI:14.15-48.57).The area under the curve was 0.92.The evaluation of publication bias was not significant(P=0.235).CONCLUSION:Although IGRAs are not sensitive enough,they provide good specificity for the accurate diagnosis of ITB,which may be helpful in the differential diagnosis of ITB from CD.展开更多
文摘Differentiating Crohn's disease(CD) and intestinal tuberculosis(ITB) has remained a dilemma for most of the clinicians in the developing world, which are endemic for ITB, and where the disease burden of inflammatory bowel disease is on the rise. Although, there are certain clinical(diarrhea/hematochezia/perianal disease common in CD; fever/night sweats common in ITB), endoscopic(longitudinal/aphthous ulcers common in CD; transverse ulcers/patulous ileocaecal valve common in ITB), histologic(caseating/confluent/large granuloma common in ITB; microgranuloma common in CD), microbiologic(positive stain/culture for acid fast-bacillus in ITB), radiologic(long segment involvement/comb sign/skip lesions common in CD; necrotic lymph node/contiguous ileocaecal involvement common in ITB), and serologic differences between CD and ITB, the only exclusive features are caseation necrosis on biopsy, positive smear for acid-fast bacillus(AFB) and/or AFB culture, and necrotic lymph node on cross-sectional imaging in ITB. However,these exclusive features are limited by poor sensitivity, and this has led to the development of multiple multi-parametric predictive models. These models are also limited by complex formulae, small sample size and lack of validation across other populations. Several new parameters have come up including the latest Bayesian meta-analysis, enumeration of peripheral blood T-regulatory cells, and updated computed tomography based predictive score. However, therapeutic anti-tubercular therapy(ATT) trial, and subsequent clinical and endoscopic response to ATT is still required in a significant proportion of patients to establish the diagnosis. Therapeutic ATT trial is associated with a delay in the diagnosis of CD, and there is a need for better modalities for improved differentiation and reduction in the need for ATT trial.
文摘目的:评估聚合酶链反应(PCR)技术检测通过活检或手术获取的肠道组织石蜡标本中结核分枝杆菌(Mycobacterium tuberculosis,MTB)DNA在鉴别克罗恩病(Crohn disease,CD)和肠结核(intestinal tuberculosis,ITB)中的可行性及价值。方法:根据来自MTB的重复插入序列IS6110设计引物,用PCR技术检测CD与ITB肠道组织蜡块标本中MTB DNA,利用基因直接测序法验证结果,分析PCR检测结果与病理特征间的关系。结果:ITB组MTB DNA检出率为32%,CD组MTB DNA检出率为0%,MTB DNA PCR法在ITB和CD鉴别诊断中的灵敏度为32%,显著高于抗酸染色(8%)和干酪样坏死(12%)(P<0.05)。MTB DNA PCR法在ITB和CD鉴别诊断中的特异度为100%,阳性预测值为100%,阴性预测值为59.5%。MTB DNA PCR阳性率在肉芽肿或多核巨细胞病理特征的标本中存在升高趋势,但差异无统计学意义。测序结果与PCR判读的结果相符。结论:PCR法用于MTBDNA检测,有助于ITB确诊,在ITB和CD的鉴别诊断中不失为一种方便快捷的病原学诊断方法。
文摘Background： Tuberculosis （TB） remains a worldwide problem. Intestinal TB （ITB） constitutes a major public health problem in developing countries and has been associated with significant morbidity and mortality. The aim of this study was to characterize the clinical, radiological, endoscopic, and pathological features of ITB and to define the strategy for establishing the diagnosis. Methods： A retrospective study （from January 2000 to June 2015） was carried out in Peking Union Medical College Hospital and all hospitalized cases were diagnosed as ITB during the study period were included. The relevant clinical information, laboratory results, microbiological, and radiological investigations were recorded. Results： Of the 85 cases, 61 cases （71.8%） were ranged from 20 to 50 years. The ileocecal region was involved in about 83.5% （71/85） of patients. About 41.2% （35/85） of patients had co-existing extra ITB, especially active pulmonary TB. Abdominal pain （82.4%） was the most common presenting symptom followed by weight loss （72.9%） and fever （64.7%）. Both T-cell spot of TB test （T-SPOT.TB） and purified protein derivatives （PPD） tests were performed in 26 patients： 20 （76.9%） positive T-SPOT.TB and 13 （50.0%） positive PPD were detected, with a statistical significant difference （P- 0.046）. Twenty cases （23.5%） were histopathology and/or pathogen confirmed TB; 27 cases （31.8%） were diagnosed by clinical manifestation consistent with ITB and evidence of active extra ITB; 38 cases （44.7%） were diagnosed by good response to diagnostic anti-TB therapy. Conclusions： ITB is difficult to diagnose even with modem medical techniques due to its nonspecific clinical and laboratory features. At present, combination of clinical, endoscopic, radiological, and pathological features continues to be the key to the diagnosis of ITB.
文摘AIM:To investigate the clinical usefulness of interferon-gamma release assays(IGRAs)in the differential diagnosis of intestinal tuberculosis(ITB)from Crohn’s disease(CD)by meta-analysis.METHODS:A systematic search of English language studies was performed.We searched the following databases:Medline,Embase,Web of Science and the Cochrane Library.The Standards for Reporting Diagnostic Accuracy initiative and Quality Assessment for Studies of Diagnostic Accuracy tool were used to assess the methodological quality of the studies.Sensitivity,specificity,and other measures of the accuracy of IGRAs in the differential diagnosis of ITB from CD were pooled and analyzed using random-effects models.Receiver operating characteristic curves were applied to summarize overall test performance.Two reviewers independently judged study eligibility while screening the citations.RESULTS:Five studies met the inclusion criteria.The average inter-rater agreement between the two reviewers for items in the quality checklist was 0.95.Analysis of IGRAs for the differential diagnosis of ITB from CD produced summary estimates as follows:sensitivity,0.74(95%CI:0.68-0.80);specificity,0.87(95%CI:0.82-0.90);positive likelihood ratio,5.98(95%CI:3.79-9.43);negative likelihood ratio,0.28(95%CI:0.18-0.43);and diagnostic odds ratio,26.21(95%CI:14.15-48.57).The area under the curve was 0.92.The evaluation of publication bias was not significant(P=0.235).CONCLUSION:Although IGRAs are not sensitive enough,they provide good specificity for the accurate diagnosis of ITB,which may be helpful in the differential diagnosis of ITB from CD.
